151 related articles for article (PubMed ID: 36527892)
1. The way of interaction between Vγ9Vδ2 T cells and tumor cells.
Zhang T; Wang J; Zhao A; Xia L; Jin H; Xia S; Shi T
Cytokine; 2023 Feb; 162():156108. PubMed ID: 36527892
[TBL] [Abstract][Full Text] [Related]
2. Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.
Rodrigues NV; Correia DV; Mensurado S; Nóbrega-Pereira S; deBarros A; Kyle-Cezar F; Tutt A; Hayday AC; Norell H; Silva-Santos B; Dias S
Cancer Immunol Res; 2018 Apr; 6(4):448-457. PubMed ID: 29358174
[TBL] [Abstract][Full Text] [Related]
3. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas.
Bouet-Toussaint F; Cabillic F; Toutirais O; Le Gallo M; Thomas de la Pintière C; Daniel P; Genetet N; Meunier B; Dupont-Bierre E; Boudjema K; Catros V
Cancer Immunol Immunother; 2008 Apr; 57(4):531-9. PubMed ID: 17764010
[TBL] [Abstract][Full Text] [Related]
4. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
Viey E; Fromont G; Escudier B; Morel Y; Da Rocha S; Chouaib S; Caignard A
J Immunol; 2005 Feb; 174(3):1338-47. PubMed ID: 15661891
[TBL] [Abstract][Full Text] [Related]
5. Production of TNF-alpha by human V gamma 9V delta 2 T cells via engagement of Fc gamma RIIIA, the low affinity type 3 receptor for the Fc portion of IgG, expressed upon TCR activation by nonpeptidic antigen.
Lafont V; Liautard J; Liautard JP; Favero J
J Immunol; 2001 Jun; 166(12):7190-9. PubMed ID: 11390467
[TBL] [Abstract][Full Text] [Related]
6. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V gamma 9V delta 2 T lymphocytes.
Poccia F; Cipriani B; Vendetti S; Colizzi V; Poquet Y; Battistini L; López-Botet M; Fournié JJ; Gougeon ML
J Immunol; 1997 Dec; 159(12):6009-17. PubMed ID: 9550399
[TBL] [Abstract][Full Text] [Related]
7. NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals.
Nedellec S; Sabourin C; Bonneville M; Scotet E
J Immunol; 2010 Jul; 185(1):55-63. PubMed ID: 20511557
[TBL] [Abstract][Full Text] [Related]
8. Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
Hoeres T; Smetak M; Pretscher D; Wilhelm M
Front Immunol; 2018; 9():800. PubMed ID: 29725332
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
10. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria.
Bessoles S; Ni M; Garcia-Jimenez S; Sanchez F; Lafont V
Eur J Immunol; 2011 Jun; 41(6):1619-28. PubMed ID: 21469127
[TBL] [Abstract][Full Text] [Related]
11. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors.
Bonneville M; Scotet E
Curr Opin Immunol; 2006 Oct; 18(5):539-46. PubMed ID: 16870417
[TBL] [Abstract][Full Text] [Related]
12. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
13. Self-activation of Vγ9Vδ2 T cells by exogenous phosphoantigens involves TCR and butyrophilins.
Laplagne C; Ligat L; Foote J; Lopez F; Fournié JJ; Laurent C; Valitutti S; Poupot M
Cell Mol Immunol; 2021 Aug; 18(8):1861-1870. PubMed ID: 34183807
[TBL] [Abstract][Full Text] [Related]
14. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
[TBL] [Abstract][Full Text] [Related]
15. Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.
Saura-Esteller J; de Jong M; King LA; Ensing E; Winograd B; de Gruijl TD; Parren PWHI; van der Vliet HJ
Front Immunol; 2022; 13():915837. PubMed ID: 35784326
[TBL] [Abstract][Full Text] [Related]
16. Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.
Castella B; Vitale C; Coscia M; Massaia M
Cell Mol Life Sci; 2011 Jul; 68(14):2419-32. PubMed ID: 21584812
[TBL] [Abstract][Full Text] [Related]
17. TCR repertoire analysis reveals phosphoantigen-induced polyclonal proliferation of Vγ9Vδ2 T cells in neonates and adults.
Fichtner AS; Bubke A; Rampoldi F; Wilharm A; Tan L; Steinbrück L; Schultze-Florey C; von Kaisenberg C; Prinz I; Herrmann T; Ravens S
J Leukoc Biol; 2020 Jun; 107(6):1023-1032. PubMed ID: 32064671
[TBL] [Abstract][Full Text] [Related]
18. Innate T cell immunity to HIV-infection. Immunotherapy with phosphocarbohydrates, a novel strategy of immune intervention?
Gougeon ML; Malkovsky M; Casetti R; Agrati C; Poccia F
Vaccine; 2002 May; 20(15):1938-41. PubMed ID: 11983250
[TBL] [Abstract][Full Text] [Related]
19. CRTAM receptor engagement by Necl-2 on tumor cells triggers cell death of activated Vγ9Vδ2 T cells.
Dessarthe B; Thedrez A; Latouche JB; Cabillic F; Drouet A; Daniel P; de La Pintière CT; Catros V; Toutirais O
J Immunol; 2013 May; 190(9):4868-76. PubMed ID: 23530148
[TBL] [Abstract][Full Text] [Related]
20. NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells.
Chauvin C; Joalland N; Perroteau J; Jarry U; Lafrance L; Willem C; Retière C; Oliver L; Gratas C; Gautreau-Rolland L; Saulquin X; Vallette FM; Vié H; Scotet E; Pecqueur C
Clin Cancer Res; 2019 Dec; 25(23):7218-7228. PubMed ID: 31506386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
